Charles River Laboratories International, Inc.

CRL · NYSE · USD

Whether three straight quarters of DSA bookings above 1x turn into durable organic revenue growth and margin recovery, or stall as research models decline and pricing stays flat.

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Demand recovery in safety assessment

    The bull case is that biotech funding and pharma budgets have turned, so stronger bookings should now convert into safety-assessment revenue growth after two years of decline.

  • Ownership of NHP supply

    Owning the Cambodian and Mauritian monkey farms secures the scarce models clients need and lowers sourcing costs, which supports both revenue and margin.

  • Portfolio simplification and cost cuts

    Divesting slower businesses while cutting costs and repurchasing shares lifts earnings per share even if the top line grows slowly.

  • Partner for AI-enabled discovery

    Management argues AI and new test methods will produce more molecules to validate, work that still passes through regulated safety testing Charles River dominates.

Bear case

  • Bookings convert slowly to revenue

    The bear case is that booked work takes several quarters to reach revenue and pricing is flat, so the bookings recovery adds little to near-term sales.

  • Research models under pressure

    North American small-model volumes, flat NIH budgets and weak early-stage company formation keep the research models segment shrinking.

  • Margin gains from portfolio actions

    Much of the second-half margin improvement comes from divestitures and an acquisition rather than operations, so it may not repeat in the following year.

  • Alternative methods and offshore rivals

    Regulators and clients push to reduce animal testing, and cheaper Chinese providers take early-stage work, both limiting long-term volume growth.

Bull and bear points

Growth & Execution

In short: DSA bookings have recovered and revenue is growing again, while North American research models shrink.

Bull · 2

  • DSA guidance moved from no forecast to growth

    A year ago management said it was too early to frame the next year and would not predict DSA; it now guides that segment to low single-digit organic growth and has raised the full-year outlook.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • DSA bookings and backlog at multi-year highs

    Net book-to-bill has been above 1x for three consecutive quarters and the backlog keeps building, which management calls the lead indicator for safety-assessment revenue into next year.

    Q2 FY2026 call
Bear · 2

  • North American research models keep shrinking

    Research models revenue fell again as small-model volumes in North America declined and occupancy at the early-stage client sites stayed weak, holding back the segment that supplies animals and related services.

    Filed financials

  • Flat pricing means growth must come from volume

    Management says pricing has not improved from recent levels and any uptick would not reach revenue until next year, so near-term growth depends on study volume and on backlog converting faster than it has.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Margins are guided higher and buybacks shrink the share count, but free cash flow has fallen and debt rose.

Bull · 2

  • Guided margin expansion of 120 to 150 basis points

    Management expects full-year operating margin to expand by roughly 120 to 150 basis points, with at least 500 basis points of sequential improvement in the second half driven by completed portfolio actions.

    Q2 FY2026 call

  • Buybacks resumed after a dry-powder pledge

    In February management said it would prioritize debt repayment and expected the diluted share count to rise; it has since repurchased $300 million of stock this year and still holds a $1 billion authorization.

    Tone shiftQ4 FY2025 → Q2 FY2026
Bear · 2

  • Free cash flow down sharply from last year

    Trailing free cash flow is $371 million, or 9.3% of revenue, against $578 million a year earlier, reflecting lower earnings plus higher bonus and deferred compensation payments.

    Filed financials

  • Net debt rose to fund deals and buybacks

    Net debt is $2.4 billion versus $2.1 billion a year earlier as acquisitions and share repurchases were funded partly with borrowings, leaving less room for further deals.

    Filed financials

Market Position

In short: Owned monkey supply is a competitive advantage, while alternative test methods threaten long-term volume.

Bull · 2

  • Owned NHP farms secure scarce study models

    With Noveprim in Mauritius and the Cambodian supplier now owned, Charles River controls the timing, quality and volume of the monkeys needed for regulated safety studies, a supply advantage few competitors can match.

    Q2 FY2026 call

  • Dominant share with large pharmaceutical clients

    Management says its share with large pharma is well above competitors and multiyear contracts underpin that work, giving Charles River first call on outsourced safety studies when budgets return.

    Q3 FY2025 call
Bear · 2

  • Regulators push to reduce animal testing

    The FDA and other agencies want alternatives used wherever the science allows, and management concedes that new test methods and AI could eventually displace some in vivo safety work.

    Q3 FY2025 call

  • Revenue fell 12.8% in the last deep downturn

    Revenue fell 12.8% between FY2008 and FY2012 and the operating margin moved from negative 34.9% to 14.7%, showing how quickly demand and pricing reverse when client funding dries up.

    Filed financials